Canine dementia: family's loss offers clues to alzheimer's
A Colorado Family’s heartbreaking story of loss is providing unprecedented insights into canine cognitive decline, potentially mirroring the progression of Alzheimer's disease in humans. The Rowe Family’s beloved dog, Ralph, was diagnosed with dementia in February 2025, after exhibiting increasingly concerning behavioral changes. His case and subsequent brain study are now informing research into both animal and human neurodegenerative diseases.
A canine model for human disease
Tara Rowe recounted to 60 Minutes how Ralph, a mellow yet playful mixed-breed, had been a constant source of comfort for her Family. Ralph provided unwavering support during challenging times, including the birth of their daughter, Eloise, who was born with esophageal atresia/tracheoesophageal fistula, and a cardiac arrest that left Jason, Ralph's owner, with cognitive issues. But in late 2024, the Family noticed a troubling shift in Ralph's behavior: increasing anxiety and confusion.
A cognitive test conducted by comparative psychologist Evan MacLean revealed significant short-term memory impairment. Ralph struggled to recall where treats were hidden, demonstrating a disconcerting inability to retain information even over short periods. This prompted a detailed examination of Ralph’s brain, revealing a pattern mirroring that seen in human Alzheimer's patients.
MRI scans revealed widespread shrinkage in Ralph's brain, with an expansion of the fluid-filled spaces within. This structural change is remarkably similar to the brain atrophy observed in individuals with Alzheimer’s. Neuropathologist Dr. Dirk Keene at the University of Washington emphasized this similarity: “You can see the dog brain has the same frontal lobe, temporal lobe, [and] occipital lobe.”
Rapamycin shows promise in slowing progression
Following Ralph's death in December, scientists at Colorado State University were able to glean further insights. A pilot study involving 12 dogs exhibiting signs of dementia explored the potential of rapamycin, an immunosuppressant drug, to slow the disease's progression. The study revealed that dogs receiving rapamycin showed fewer microglial cells, which are associated with inflammation linked to dementia, compared to a control group.
“The dogs who took rapamycin had fewer microglial cells,” explained molecular biologist Julie Moreno. “Ralph’s results were similar.” While rapamycin isn't a cure, the findings offer a glimmer of hope for developing therapies for both canine and human dementia, as the underlying mechanisms appear surprisingly comparable.
Researchers highlight that these findings are particularly compelling because they offer a window into disease mechanisms. While a broadly effective treatment for dementia remains elusive for both species, the research offers new avenues for investigation. The investigation also underscores how closely linked animal models can be to human disease.
Dr. Keene points out that understanding canine dementia could provide critical insights into preventing and treating Alzheimer's in humans.